DHRS2

Across TCGA pan-cancer cohorts, DHRS2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DHRS2 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher DHRS2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DHRS2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, DLBC, and BLCA are the cancer types where DHRS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.080	0.533	<.001	18	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
BLCA	DFS	Median	All	0.132	0.626	.006	12	view →
COAD	OS	Median	All	0.172	0.870	<.001	12	view →
SKCM	DFS	Median	II,III,IV	0.796	0.538	.027	6	view →
LGG	OS	Median	All	0.307	0.799	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DHRS2–ESCA (DFS)

Open the ESCA breakdown →